-
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric CancerDaiichi Sankyo2023-11-09 20:57:08ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
-
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research InstituteDaiichi Sankyo2020-07-24 10:37:21Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research
-
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2020-08-03 09:22:50ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung
-
Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual MeetingDaiichi Sankyo2020-07-24 10:39:26Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting
-
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric CancerDaiichi Sankyo2023-11-10 06:54:49ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer
-
New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI® approved in EuropeDaiichi Sankyo2020-08-03 09:23:48New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI®
-
Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary EndpointDaiichi Sankyo2020-01-27 09:31:00Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
-
ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based RegimensDaiichi Sankyo2020-08-03 09:24:15ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More
-
Large Real-World Data Confirm Safety and Effectiveness of LIXIANA®▼ (edoxaban) in Routine Clinical Practice for Elderly AF Patients with ComorbiditiesDaiichi Sankyo2020-08-03 09:24:40Large Real-World Data Confirm Safety and Effectiveness of LIXIANA®▼ (edoxaban) in Routine Clinical Practice
-
DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2 Positive Metastatic Breast Cancer TrialDaiichi Sankyo2020-07-24 10:46:06DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2
